Japan’s Ministry of Health, Labour and Welfare approved the use of Remdesivir to treat new coronary pneumonia, giving priority to patients with severe illness, the Japan Broadcasting Association (NHK) reported Wednesday. It is the first drug in Japan to be approved for the treatment of new coronary pneumonia.
Japanese Prime Minister Shinzo Abe also responded to the issue on the 7th, as the drug took only three days to report the incident with “unprecedented speed” after the drug company applied for the drug company’s 4th application to its final approval.
Japan’s Kyodo news agency, Asahi TV and other media reports, Japanese Prime Minister Shinzo Abe in the 6th network program said that the 7th approval of Redsie wei for the treatment of new coronary pneumonia. Gilead Sciences, a Us-china drugmaker, applied to Japan’s Ministry of Health, Labour and Welfare on May 4 for approval of Redsie’s use in Japan. Japan’s Ministry of Labor has adopted a system of “exceptional approval”.
At present, the supply of the drug in Japan is still very small, the minister of the Ministry of Health, Yukio Kato, said that the amount of drugs Gilead to Japan, there is still a need to coordinate. Efforts will be made to obtain the necessary medicines so that seriously ill patients can use them as quickly as possible (Ridsywe).
Reddit was once considered the most promising drug to fight the new coronavirus, developed by California-based Gilead Sciences,media said. Redciewe has shown some hope in the treatment of SARS and Middle East Respiratory Syndrome (MERS), both of which are caused by coronaviruses.
However, while some countries, such as the United States, have high hopes for Redsey, some experts remain sceptical about its true efficacy. On the same day that the results of the US trial were published, the results of clinical trials in China published in the Lancet were not encouraging, with low cure rates and high side effects becoming their Achilles heel.
Daniel O’Day, Gilead’s chairman and chief executive, later issued an open letter in response, saying that Redciewe is still a drug under study and has not yet been approved in any country in the world, and that a broader effort is needed to determine whether it is a safe and effective treatment.
This time Japan “special approval” of Redsiwe, the original review procedures to simplify, causing a number of Japanese media concern, some domestic experts asked the government to act carefully. In addition, Avigan, a new treatment for coronary pneumonia developed by Japanese producers, has been slow to get government recognition, and domestic public opinion has questioned it. Yahoo News (Japanese version) said that both Redsiewe or Fabilau are at serious risk of side effects, and that Rhedesiwec or lead to liver and kidney dysfunction, fabila or birth deformities cannot be simply treated as prescription drugs.
In response to the above-mentioned controversy, Japanese Prime Minister Shinzo Abe 7 in an interview with the Nikkei News about Redsie’s approval, and stressed that “will gather the wisdom of enterprises and researchers all over Japan, the world, and strive to bring the treatment to patients as soon as possible.”
Regarding The Japan-developed Fapilawe, Mr Abe said he would “target approval within this month”. Regarding the new coronary pneumonia vaccine, Abe said that “research and development is under way at the Dongda, Anda and National Institutes of Infectious Diseases, and it is generally believed that vaccine development usually takes nearly a year, with the possibility of clinical trials in humans starting around this fall”.
According to Japanese media, Mr. Fabilawi now has a reserve of 700,000 people in Japan, while Mr. Abe stressed that “it will increase to 2 million.”